Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma

Recruiting

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(10 sites)

France

Centre Hospitalier d'Annecy, Annecy

Institut Sainte Catherine, Avignon

Centre Hospitalier de Bayeux, Bayeux

Centre François Baclesse, Caen

Polyclinique du Parc Elsan, Caen

Ghpso Creil, Creil

Centre Hospitalier de Lorient, Lorient

GHR Mulhouse Sud Alsace, Mulhouse

CHU, Saint-Etienne

Centre Hospitalier de Tours, Tours